Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies

BACKGROUND: Successful treatments of patients with somatostatin receptor (SSTR)-overexpressing neuroendocrine tumours (NET) comprise somatostatin-analogue lutetium-177-labelled octreotate ((177)Lu-TATE) treatment, also referred to as peptide receptor radionuclide therapy (PRRT), and temozolomide (TM...

Descripción completa

Detalles Bibliográficos
Autores principales: Bison, Sander M., Haeck, Joost C., Bol, K., Koelewijn, S. J., Groen, H. C., Melis, M., Veenland, J. F., Bernsen, M. R., de Jong, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639542/
https://www.ncbi.nlm.nih.gov/pubmed/26553049
http://dx.doi.org/10.1186/s13550-015-0142-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639542/
https://www.ncbi.nlm.nih.gov/pubmed/26553049
http://dx.doi.org/10.1186/s13550-015-0142-y

Ejemplares similares